These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Evaluation of donor-specific transfusion sources: unique failure of bone marrow cells to induce prolonged skin allograft survival with anti-CD154 monoclonal antibody. Markees TG; Pearson T; Cuthbert A; Pearson AL; Shultz LD; Leif J; Phillips NE; Mordes JP; Greiner DL; Rossini AA Transplantation; 2004 Dec; 78(11):1601-8. PubMed ID: 15591948 [TBL] [Abstract][Full Text] [Related]
10. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. Markees TG; Phillips NE; Gordon EJ; Noelle RJ; Shultz LD; Mordes JP; Greiner DL; Rossini AA J Clin Invest; 1998 Jun; 101(11):2446-55. PubMed ID: 9616216 [TBL] [Abstract][Full Text] [Related]
11. Prolonged survival of rat islet and skin xenografts in mice treated with donor splenocytes and anti-CD154 monoclonal antibody. Gordon EJ; Markees TG; Phillips NE; Noelle RJ; Shultz LD; Mordes JP; Rossini AA; Greiner DL Diabetes; 1998 Aug; 47(8):1199-206. PubMed ID: 9703317 [TBL] [Abstract][Full Text] [Related]
12. Specific acceptance of cardiac allografts after treatment with antibodies to CD80 and CD86 in mice. Bashuda H; Seino K; Kano M; Sato K; Azuma M; Yagita H; Okumura K Transplant Proc; 1996 Apr; 28(2):1039-41. PubMed ID: 8623220 [No Abstract] [Full Text] [Related]
14. Blockade of CD40-mediated signaling is sufficient for inducing islet but not skin transplantation tolerance. Phillips NE; Markees TG; Mordes JP; Greiner DL; Rossini AA J Immunol; 2003 Mar; 170(6):3015-23. PubMed ID: 12626555 [TBL] [Abstract][Full Text] [Related]
15. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb. Lu L; Li W; Zhong C; Qian S; Fung JJ; Thomson AW; Starzl TE Transplantation; 1999 Sep; 68(6):747-57. PubMed ID: 10515374 [TBL] [Abstract][Full Text] [Related]
16. Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand. Markees TG; Phillips NE; Noelle RJ; Shultz LD; Mordes JP; Greiner DL; Rossini AA Transplantation; 1997 Jul; 64(2):329-35. PubMed ID: 9256196 [TBL] [Abstract][Full Text] [Related]
17. Neutralizing IL-7 promotes long-term allograft survival induced by CD40/CD40L costimulatory blockade. Wang Y; Dai H; Liu Z; Cheng X; Tellides G; Dai Z Am J Transplant; 2006 Dec; 6(12):2851-60. PubMed ID: 17062001 [TBL] [Abstract][Full Text] [Related]
18. Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. Fu F; Li W; Lu L; Thomson AW; Fung JJ; Qian S Transplant Proc; 1999; 31(1-2):1244. PubMed ID: 10083555 [No Abstract] [Full Text] [Related]
19. Blockade of CD40L/CD40 costimulatory pathway in a DST presensitization model of islet allograft leads to a state of Allo-Ag specific tolerance and permits subsequent engraftment of donor strain islet or heart allografts. Zheng XX; Li Y; Li XC; Roy-Chaudhury P; Nickerson P; Tian Y; Sayegh MH; Strom TB Transplant Proc; 1999; 31(1-2):627-8. PubMed ID: 10083268 [No Abstract] [Full Text] [Related]
20. Heart, but not skin, allografts from donors lacking Flt3 ligand exhibit markedly prolonged survival time. Wang Z; Castellaneta A; De Creus A; Shufesky WJ; Morelli AE; Thomson AW J Immunol; 2004 May; 172(10):5924-30. PubMed ID: 15128773 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]